J Gynecol Oncol.  2013 Jan;24(1):1-2. 10.3802/jgo.2013.24.1.1.

Coexisting carcinoma in endometrial hyperplasia: does more risk factor mean better discrimination?

• Kang S

• KMID: 2288553
• DOI: http://doi.org/10.3802/jgo.2013.24.1.1

Abstract

No abstract available.

MeSH Terms

Risk Factors

Reference

1. Clark TJ, Neelakantan D, Gupta JK. The management of endometrial hyperplasia: an evaluation of current practice. Eur J Obstet Gynecol Reprod Biol. 2006. 125:259–264.

2. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia: a long-term study of "untreated" hyperplasia in 170 patients. Cancer. 1985. 56:403–412.

3. Lacey JV Jr, Sherman ME, Rush BB, Ronnett BM, Ioffe OB, Duggan MA, et al. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol. 2010. 28:788–792.

4. Lee SY, Kim MK, Park H, Yoon BS, Seong SJ, Kang JH, et al. The effectiveness of levonorgestrel releasing intrauterine system in the treatment of endometrial hyperplasia in Korean women. J Gynecol Oncol. 2010. 21:102–105.

5. Buttini MJ, Jordan SJ, Webb PM. The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: an Australian study and systematic review. Aust N Z J Obstet Gynaecol. 2009. 49:316–322.